icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
Voir aussi
Décision d'accès précoce
22/12/2022
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
qVNQsWCvY9S4uVkY